GERN Stock Analysis: Buy, Sell, or Hold?
GERN - Geron Corp
$1.35
0.01 (0.75%)
▲
5d:
+17.39%
30d:
+7.14%
90d:
-12.34%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 7.6/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GERN is fairly valued with market pricing in 0.5% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: GERN is fairly valued with market pricing in 0.5% annual growth. Fine to hold or accumulate slowly on dips.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.35, which is considered extended relative to its 30-day fair value range of $1.15 to $1.28. The stock's valuation (Forward PE: 20.6) is in line with its historical norms (20.3). At these levels, the market is pricing in 0.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a downtrend. The price is approaching resistance at $1.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GERN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+153.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GERN is in a downtrend. The price is approaching resistance at $1.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GERN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+153.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.15 -
$1.28
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding GERN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+5.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 153.7% below Wall St target ($3.40)
- NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$1.15 -
$1.28
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.08
Resistance Level
$1.37
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.62
Wall Street Target
$3.40
(+153.7%)
Revenue Growth (YoY)
30.9%
Profit Margin
-34.3%
Valuation Premium vs History
+0.5% premium
PE vs Historical
20.6 vs 20.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.5%
(market-implied from PE analysis)
1-Year Target
$1.35
(+1%)
2-Year Target
$1.35
(+1%)
3-Year Target
$1.36
(+2%)
3-Yr Target (if PE normalizes)
(PE: 21→20)
PE COMPRESSION
$1.34
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 23, 2026 3:31 PM ET
Data refreshes hourly during market hours. Next update: 4:31 PM
Data refreshes hourly during market hours. Next update: 4:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
